Prostate cancer screening: Who should we screen? Defining high-risk populations
Journal of Clinical Urology · 2026-07 · 19 (4) · 362-367
DOI: 10.1177/20514158261443413 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Urology, online erschienen am 03.06.2026. Verfasst von Cynthia O’Sullivan und 2 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Introduction
Interest in targeted prostate cancer screening has increased following the UK National Screening Committee’s November 2025 draft recommendation and public consultation, which supported a risk-stratified approach rather than population-wide prostate-specific antigen (PSA) screening. This literature review summarises current evidence for screening in high-risk groups, including men of Black ethnicity, those with a family history of prostate cancer, and carriers of pathogenic BRCA1/2 variants.
Methods
A narrative review of landmark randomised screening trials, guideline documents, modelling studies, and prospective cohort data was performed, focusing on the effectiveness and limitations of targeted screening strategies in high-risk populations.
Results
PSA-based screening reduces prostate cancer mortality in some settings but remains associated with substantial overdiagnosis. Contemporary pathways incorporating pre-biopsy magnetic resonance imaging (MRI) and active surveillance have improved the balance between benefit and harm. Recent UK modelling suggests that population screening is unlikely to be cost-effective, whereas targeted screening may offer greater value in selected high-risk groups, particularly BRCA2 carriers and potentially men of Black ethnicity.
Discussion
Current evidence supports a move away from universal PSA screening towards structured, risk-stratified early detection. The strongest rationale exists for targeted screening in men with pathogenic BRCA2 variants, while evidence for other high-risk groups continues to evolve. Ongoing studies, including TRANSFORM, will be important in defining future UK screening policy. Level of evidence: Not applicable.
Zitieren
APA
O’Sullivan, C., SanzGómez, I., & Challacombe, B. (2026). Prostate cancer screening: Who should we screen? Defining high-risk populations. Journal of Clinical Urology, 19(4), 362-367. https://doi.org/10.1177/20514158261443413
Vancouver
O’Sullivan C, SanzGómez I, Challacombe B. Prostate cancer screening: Who should we screen? Defining high-risk populations. Journal of Clinical Urology. 2026;19(4):362-367. doi:10.1177/20514158261443413
BibTeX
@article{OSullivan2026,
author = {O’Sullivan, Cynthia and SanzGómez, Isabel and Challacombe, Ben},
title = {Prostate cancer screening: Who should we screen? Defining high-risk populations},
journal = {Journal of Clinical Urology},
year = {2026},
volume = {19},
number = {4},
pages = {362--367},
doi = {10.1177/20514158261443413}
}
EUVIMED